💉 Once-Weekly Injections for Type 2 Diabetes

💉 Once-Weekly Injections for Type 2 Diabetes
Scientific Evidence, Benefits & Adverse Effects
Once-weekly injectable medicines have become an important treatment option for type 2 diabetes, particularly the GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide.
Examples include semaglutide, dulaglutide and tirzepatide. The 2026 American Diabetes Association Standards of Care recognize GLP-1–based therapies as highly effective glucose-lowering treatments, with additional benefits related to body weight and, for some agents, cardiovascular and kidney outcomes. �
Diabetes Journals
🧬 How do these injections work?
GLP-1–based medicines can:
Increase insulin secretion when blood glucose is elevated
Reduce inappropriate glucagon secretion
Slow gastric emptying
Increase satiety and reduce food intake
Improve blood-glucose control
Promote weight loss in many patients
These effects occur through different but related mechanisms depending on the medication. �
Diabetes Journals
🔬 What does the evidence show?
In the SUSTAIN-6 randomized clinical trial, 3,297 people with type 2 diabetes at high cardiovascular risk received once-weekly semaglutide or placebo for 104 weeks.
The composite outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in:
6.6% with semaglutide vs 8.9% with placebo.
This demonstrated cardiovascular safety and was associated with fewer major cardiovascular events in this high-risk study population. �
New England Journal of Medicine
The ADA 2026 Standards also report that semaglutide, dulaglutide and liraglutide have demonstrated cardiovascular benefit, while semaglutide has evidence for certain kidney outcomes. Tirzepatide has demonstrated substantial glucose- and weight-lowering effects, with cardiovascular outcomes continuing to be evaluated.
Diabetes Journals
⚠️ Adverse Effects
The most commonly reported adverse effects are gastrointestinal:
Nausea
Vomiting
Diarrhea
Constipation
Abdominal discomfort
Reduced appetite
Indigestion/reflux
These effects are often more prominent when treatment is started or the dose is increased. Gradual dose escalation can improve tolerability.
New England Journal of Medicine +1
Important but less common concerns
Pancreatitis: Acute pancreatitis has been reported; treatment should be stopped and medically evaluated if pancreatitis is suspected.
Diabetes Journals
Gallbladder disease: Gallstones and gallbladder complications can occur.
Diabetes Journals
Diabetic retinopathy: Rapid improvement in glucose control can be associated with worsening of diabetic retinopathy in some high-risk patients. Close eye monitoring is particularly important in patients with pre-existing retinopathy.
New England Journal of Medicine +1
Hypoglycemia: The risk is generally lower when GLP-1–based medicines are used alone, but it can increase when combined with insulin or sulfonylureas. Medication doses may therefore need adjustment.
Diabetes Journals
Thyroid C-cell tumor warning: Thyroid C-cell tumors have been observed in rodents. The relevance to humans has not been established; these medicines should be avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, according to applicable prescribing information. �
Diabetes Journals
🌿 Important clinical message
A once-weekly injection is not a "cure" for diabetes or a replacement for lifestyle management.
It should be prescribed after considering:
HbA1c + fasting/post-meal glucose + body weight + kidney function + cardiovascular history + current medications + contraindications.
Diet, physical activity, sleep, weight management and regular monitoring remain important components of diabetes care.
📌 Article conclusion
“Once-weekly GLP-1–based injections have strong clinical evidence for improving glycemic control and, for selected medicines, reducing cardiovascular risk and body weight in people with type 2 diabetes. However, they are prescription medicines and can cause significant adverse effects. Appropriate patient selection, gradual dose escalation and medical monitoring are essential for safe treatment.”